Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation, filed this Current Report on Form 8-K on August 14, 2023. The filing serves to announce the Company's results of operations for the fiscal quarter ended June 30, 2023. The Company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K acts as a notification that a press release containing these details has been issued. The specific financial data is contained in Exhibit 99.1 (Press Release dated August 14, 2023), which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the text provided. It solely references the issuance of the press release regarding the Q2 2023 results.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are presumed to be located in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2023 revenue, net loss, and cash burn figures.
- Verify the Company's cash position and runway as disclosed in the press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if there were any changes in the Company's capital structure or debt obligations during the quarter.